Skip to main content
Top

10-05-2023 | Case-Based Insights: Oncology and Hematology | Training Course

32/♀ with planned induction therapy for newly diagnosed acute lymphocytic leukaemia – Case 5

After obtaining all the necessary findings, you diagnose a 32-year-old female patient with Philadelphia-negative common ALL. Then you initiate induction therapy in conformity with the GMALL protocol. What do you have to consider, and what could the strategy for anti-infective prophylaxis look like here?

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine